JP7652772B2 - 置換ピラゾール化合物 - Google Patents

置換ピラゾール化合物 Download PDF

Info

Publication number
JP7652772B2
JP7652772B2 JP2022525376A JP2022525376A JP7652772B2 JP 7652772 B2 JP7652772 B2 JP 7652772B2 JP 2022525376 A JP2022525376 A JP 2022525376A JP 2022525376 A JP2022525376 A JP 2022525376A JP 7652772 B2 JP7652772 B2 JP 7652772B2
Authority
JP
Japan
Prior art keywords
triazolo
pyridin
isopropyl
pyrazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501956A5 (enExample
JP2023501956A (ja
Inventor
パスヌーリ，ラクスマン
ラトナ クマール，スリーカンタ
ビーラ ベンカタ スリニバス，ピタニ
ボガディ，ビクラム
クンチタパタム ドゥライサミー，スリニバサン
レディ，アヌパマ カンディ ラマチャンドラ
クマール アヌムラ，ルシト
ジェイ ディックマン，アラリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023501956A publication Critical patent/JP2023501956A/ja
Publication of JP2023501956A5 publication Critical patent/JP2023501956A5/ja
Application granted granted Critical
Publication of JP7652772B2 publication Critical patent/JP7652772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022525376A 2019-11-01 2020-10-30 置換ピラゾール化合物 Active JP7652772B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962929299P 2019-11-01 2019-11-01
US62/929,299 2019-11-01
PCT/US2020/058081 WO2021087181A1 (en) 2019-11-01 2020-10-30 Substituted pyrazole compounds as toll receptor inhibitors

Publications (3)

Publication Number Publication Date
JP2023501956A JP2023501956A (ja) 2023-01-20
JP2023501956A5 JP2023501956A5 (enExample) 2023-11-07
JP7652772B2 true JP7652772B2 (ja) 2025-03-27

Family

ID=73544353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525376A Active JP7652772B2 (ja) 2019-11-01 2020-10-30 置換ピラゾール化合物

Country Status (6)

Country Link
US (1) US20230117470A1 (enExample)
EP (1) EP4051388A1 (enExample)
JP (1) JP7652772B2 (enExample)
KR (1) KR20220097434A (enExample)
CN (1) CN114929345B (enExample)
WO (1) WO2021087181A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
EP4436975A1 (en) * 2021-11-23 2024-10-02 Genentech, Inc. Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2025261449A1 (zh) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 一种parp1抑制剂吡啶酰胺类化合物、中间体及其制备方法
WO2026002036A1 (zh) * 2024-06-26 2026-01-02 北京双鹤润创科技有限公司 一种化合物及其用途
CN119684287A (zh) * 2024-12-18 2025-03-25 烟台新药创制山东省实验室 4-(3-(哌啶-4-基)-1H-吡唑-5-基)-1H-吡咯[2,3-b]吡啶衍生物及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010058858A1 (ja) 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
JP2011530485A (ja) 2008-05-30 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたピラゾール、１，２，４−オキサジアゾールおよび１，３，４−オキサジアゾール
JP2012505891A (ja) 2008-10-17 2012-03-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
WO2019125977A1 (en) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company 4-azaindole compounds
WO2019136147A1 (en) 2018-01-03 2019-07-11 The Board Of Trustees Of The University Of Illinois Toll-like receptor signaling inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1971594A2 (en) * 2005-11-21 2008-09-24 Biogen Idec MA Inc. Substituted pyrazalones
JP2012102018A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc アミド化合物
CA2878792A1 (en) * 2012-07-12 2014-01-16 Chiesi Farmaceutici S.P.A. Inhibition of enzymes
US9550778B2 (en) * 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
CN110869360B (zh) * 2017-07-12 2023-12-15 百时美施贵宝公司 作为rock抑制剂的苯乙酰胺类

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530485A (ja) 2008-05-30 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたピラゾール、１，２，４−オキサジアゾールおよび１，３，４−オキサジアゾール
JP2012505891A (ja) 2008-10-17 2012-03-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物
WO2010058858A1 (ja) 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
WO2019125977A1 (en) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company 4-azaindole compounds
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
WO2019136147A1 (en) 2018-01-03 2019-07-11 The Board Of Trustees Of The University Of Illinois Toll-like receptor signaling inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cocconcelli, Giuseppe et al.，Aryl azoles with neuroprotective activity-Parallel synthesis and attempts at target identification，Bioorganic & Medicinal Chemistry，2008年，16(4)，2043-2052
REGISTRY（STN）[online]，CAS登録番号1784996-40-2（Entered STN: 21 Jun 2015）、CAS登録番号1784541-82-7（Entered STN: 19 Jun 2015） [検索日 2024.08.09]
Turchin, K. F. et al.，Synthesis, structure and properties of pyrazolo[4,3-b]quinuclidine derivatives，Khimiya Geterotsiklicheskikh Soedinenii，1985年，(9)，1248-1256

Also Published As

Publication number Publication date
WO2021087181A1 (en) 2021-05-06
EP4051388A1 (en) 2022-09-07
KR20220097434A (ko) 2022-07-07
CN114929345A (zh) 2022-08-19
CN114929345B (zh) 2024-07-23
US20230117470A1 (en) 2023-04-20
JP2023501956A (ja) 2023-01-20

Similar Documents

Publication Publication Date Title
JP7652772B2 (ja) 置換ピラゾール化合物
USRE49880E1 (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
KR102742178B1 (ko) Tlr 억제제로서 유용한 치환된 인돌 화합물
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN111819176A (zh) 4-氮杂吲哚化合物
CN111448190A (zh) 取代的吲哚化合物
CN107709322B (zh) 作为抗癌剂的三环化合物
JP7629007B2 (ja) 置換二環ヘテロアリール化合物
TW201629067A (zh) 稠合五環咪唑衍生物
TW201514145A (zh) 作為ｂｔｋ抑制劑的初級甲醯胺
CN106414432A (zh) 选择性取代的喹啉化合物
KR20180114910A (ko) 수용체-상호작용 단백질 키나제 1의 억제제
CN113164476A (zh) Dyrk1/clk的小分子抑制剂及其用途
CN112955450A (zh) 经取代的吲哚和吲唑化合物
CN112135818A (zh) 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途
CN114126713A (zh) 经取代的苯并咪唑酮化合物
KR20250048005A (ko) 타이로신 키나제 2 저해제 및 이의 용도
TW202613115A (zh) Btk降解劑及其用途
HK40104906A (zh) 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
CN117597333A (zh) 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
HK40076948B (zh) Kras g12d抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250314

R150 Certificate of patent or registration of utility model

Ref document number: 7652772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150